Phosphodiesterase 4 inhibition attenuates plasma volume loss and transvascular exchange in volume-expanded mice

Yueh Chen Lin, Roger H. Adamson, Joyce F. Clark, Rolf K. Reed, Fitz Roy E Curry

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We tested the hypothesis that inhibition of phosphodiesterase 4 (PDE4) with rolipram to increase vascular endothelial cAMP and stabilize the endothelial barrier would attenuate the action of endogenous atrial natriuretic peptide (ANP) to increase vascular permeability to the plasma protein albumin after an acute plasma volume expansion. After rolipram pretreatment (8 mg (kg body wt) -1, intraperitoneal, 30 min) more than 95% of the peak increase in plasma volume after volume expansion (4.5% bovine serum albumin, 114 μl (g body wt) -1 h -1, 15 min) remained in the vascular space 75 min after the end of infusion, whereas only 67% of the fluid was retained in volume-expanded animals with no rolipram pretreatment. Rolipram significantly decreased 30 min fluorescently labelled albumin clearance (μl (g dry wt) -1) relative to untreated volume-expanded controls in skin (e.g. back, 10.4 ± 1.6vs. 19.5 ± 3.6,P= 0.04), muscle (e.g. hamstring, 15.0 ± 1.9vs.20.8 ± 1.4,P= 0.04) and in colon, caecum, and rectum (average reduction close to 50%). The mass of muscle and skin tissue accounted for 70% of volume-expansion-dependent albumin shifts from plasma to interstitium. The results are consistent with observations that the PDE4 inhibitor rolipram attenuates ANP-induced increases in vascular permeability after infusion of exogenous ANP and observations of elevated central venous pressure after a similar volume expansion in mice with selective deletion of the endothelial ANP receptor. These observations may form the basis for new strategies to retain intravenous fluid containing macromolecules.

Original languageEnglish (US)
Pages (from-to)309-322
Number of pages14
JournalJournal of Physiology
Volume590
Issue number2
DOIs
StatePublished - Jan 2012

Fingerprint

Type 4 Cyclic Nucleotide Phosphodiesterase
Rolipram
Plasma Volume
Atrial Natriuretic Factor
Capillary Permeability
Serum Albumin
Blood Vessels
Atrial Natriuretic Factor Receptors
Phosphodiesterase 4 Inhibitors
Skin
Central Venous Pressure
Bovine Serum Albumin
Rectum
Blood Proteins
Albumins
Colon
Muscles

ASJC Scopus subject areas

  • Physiology

Cite this

Phosphodiesterase 4 inhibition attenuates plasma volume loss and transvascular exchange in volume-expanded mice. / Lin, Yueh Chen; Adamson, Roger H.; Clark, Joyce F.; Reed, Rolf K.; Curry, Fitz Roy E.

In: Journal of Physiology, Vol. 590, No. 2, 01.2012, p. 309-322.

Research output: Contribution to journalArticle

Lin, Yueh Chen ; Adamson, Roger H. ; Clark, Joyce F. ; Reed, Rolf K. ; Curry, Fitz Roy E. / Phosphodiesterase 4 inhibition attenuates plasma volume loss and transvascular exchange in volume-expanded mice. In: Journal of Physiology. 2012 ; Vol. 590, No. 2. pp. 309-322.
@article{e25c57de6ef745cfa9e17b95ebc587d1,
title = "Phosphodiesterase 4 inhibition attenuates plasma volume loss and transvascular exchange in volume-expanded mice",
abstract = "We tested the hypothesis that inhibition of phosphodiesterase 4 (PDE4) with rolipram to increase vascular endothelial cAMP and stabilize the endothelial barrier would attenuate the action of endogenous atrial natriuretic peptide (ANP) to increase vascular permeability to the plasma protein albumin after an acute plasma volume expansion. After rolipram pretreatment (8 mg (kg body wt) -1, intraperitoneal, 30 min) more than 95{\%} of the peak increase in plasma volume after volume expansion (4.5{\%} bovine serum albumin, 114 μl (g body wt) -1 h -1, 15 min) remained in the vascular space 75 min after the end of infusion, whereas only 67{\%} of the fluid was retained in volume-expanded animals with no rolipram pretreatment. Rolipram significantly decreased 30 min fluorescently labelled albumin clearance (μl (g dry wt) -1) relative to untreated volume-expanded controls in skin (e.g. back, 10.4 ± 1.6vs. 19.5 ± 3.6,P= 0.04), muscle (e.g. hamstring, 15.0 ± 1.9vs.20.8 ± 1.4,P= 0.04) and in colon, caecum, and rectum (average reduction close to 50{\%}). The mass of muscle and skin tissue accounted for 70{\%} of volume-expansion-dependent albumin shifts from plasma to interstitium. The results are consistent with observations that the PDE4 inhibitor rolipram attenuates ANP-induced increases in vascular permeability after infusion of exogenous ANP and observations of elevated central venous pressure after a similar volume expansion in mice with selective deletion of the endothelial ANP receptor. These observations may form the basis for new strategies to retain intravenous fluid containing macromolecules.",
author = "Lin, {Yueh Chen} and Adamson, {Roger H.} and Clark, {Joyce F.} and Reed, {Rolf K.} and Curry, {Fitz Roy E}",
year = "2012",
month = "1",
doi = "10.1113/jphysiol.2011.213447",
language = "English (US)",
volume = "590",
pages = "309--322",
journal = "Journal of Physiology",
issn = "0022-3751",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Phosphodiesterase 4 inhibition attenuates plasma volume loss and transvascular exchange in volume-expanded mice

AU - Lin, Yueh Chen

AU - Adamson, Roger H.

AU - Clark, Joyce F.

AU - Reed, Rolf K.

AU - Curry, Fitz Roy E

PY - 2012/1

Y1 - 2012/1

N2 - We tested the hypothesis that inhibition of phosphodiesterase 4 (PDE4) with rolipram to increase vascular endothelial cAMP and stabilize the endothelial barrier would attenuate the action of endogenous atrial natriuretic peptide (ANP) to increase vascular permeability to the plasma protein albumin after an acute plasma volume expansion. After rolipram pretreatment (8 mg (kg body wt) -1, intraperitoneal, 30 min) more than 95% of the peak increase in plasma volume after volume expansion (4.5% bovine serum albumin, 114 μl (g body wt) -1 h -1, 15 min) remained in the vascular space 75 min after the end of infusion, whereas only 67% of the fluid was retained in volume-expanded animals with no rolipram pretreatment. Rolipram significantly decreased 30 min fluorescently labelled albumin clearance (μl (g dry wt) -1) relative to untreated volume-expanded controls in skin (e.g. back, 10.4 ± 1.6vs. 19.5 ± 3.6,P= 0.04), muscle (e.g. hamstring, 15.0 ± 1.9vs.20.8 ± 1.4,P= 0.04) and in colon, caecum, and rectum (average reduction close to 50%). The mass of muscle and skin tissue accounted for 70% of volume-expansion-dependent albumin shifts from plasma to interstitium. The results are consistent with observations that the PDE4 inhibitor rolipram attenuates ANP-induced increases in vascular permeability after infusion of exogenous ANP and observations of elevated central venous pressure after a similar volume expansion in mice with selective deletion of the endothelial ANP receptor. These observations may form the basis for new strategies to retain intravenous fluid containing macromolecules.

AB - We tested the hypothesis that inhibition of phosphodiesterase 4 (PDE4) with rolipram to increase vascular endothelial cAMP and stabilize the endothelial barrier would attenuate the action of endogenous atrial natriuretic peptide (ANP) to increase vascular permeability to the plasma protein albumin after an acute plasma volume expansion. After rolipram pretreatment (8 mg (kg body wt) -1, intraperitoneal, 30 min) more than 95% of the peak increase in plasma volume after volume expansion (4.5% bovine serum albumin, 114 μl (g body wt) -1 h -1, 15 min) remained in the vascular space 75 min after the end of infusion, whereas only 67% of the fluid was retained in volume-expanded animals with no rolipram pretreatment. Rolipram significantly decreased 30 min fluorescently labelled albumin clearance (μl (g dry wt) -1) relative to untreated volume-expanded controls in skin (e.g. back, 10.4 ± 1.6vs. 19.5 ± 3.6,P= 0.04), muscle (e.g. hamstring, 15.0 ± 1.9vs.20.8 ± 1.4,P= 0.04) and in colon, caecum, and rectum (average reduction close to 50%). The mass of muscle and skin tissue accounted for 70% of volume-expansion-dependent albumin shifts from plasma to interstitium. The results are consistent with observations that the PDE4 inhibitor rolipram attenuates ANP-induced increases in vascular permeability after infusion of exogenous ANP and observations of elevated central venous pressure after a similar volume expansion in mice with selective deletion of the endothelial ANP receptor. These observations may form the basis for new strategies to retain intravenous fluid containing macromolecules.

UR - http://www.scopus.com/inward/record.url?scp=84862907998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862907998&partnerID=8YFLogxK

U2 - 10.1113/jphysiol.2011.213447

DO - 10.1113/jphysiol.2011.213447

M3 - Article

VL - 590

SP - 309

EP - 322

JO - Journal of Physiology

JF - Journal of Physiology

SN - 0022-3751

IS - 2

ER -